Kalkine has a fully transformed New Avatar.
Last update at 2025-06-06T06:11:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Revenues Working Against SomnoMed Limited's (ASX:SOM) Share Price
Mon 17 Apr 23, 08:53 PMThe past five years for SomnoMed (ASX:SOM) investors has not been profitable
Tue 28 Feb 23, 09:23 PMA SomnoMed Limited (ASX:SOM) insider increased their holdings by 167% last year
Tue 01 Nov 22, 09:27 PMSomnoMed's North America Q1 revenue growth leads the way
Fri 28 Oct 22, 07:06 PMInvestors in SomnoMed (ASX:SOM) have unfortunately lost 64% over the last five years
Wed 21 Sep 22, 09:02 PMEdited Transcript of SOM.AX earnings conference call or presentation 23-Aug-22 3:00am GMT
Tue 23 Aug 22, 03:00 AMSomnoMed posts record Q4 and delivers on FY22 revenue guidance
Tue 26 Jul 22, 07:45 PMDoes SomnoMed (ASX:SOM) Have A Healthy Balance Sheet?
Tue 14 Jun 22, 12:46 AMBreakdown | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 |
Income before tax | -11.27063M | -7.04526M | -3.49570M | -0.73390M | 0.75M |
Minority interest | - | - | - | - | - |
Net income | -12.24173M | -7.99904M | -4.43697M | -1.19301M | -1.11854M |
Selling general administrative | 18.01M | 13.11M | 12.62M | 11.18M | 10.05M |
Selling and marketing expenses | 26.18M | 24.49M | 19.74M | 15.58M | 15.44M |
Gross profit | 55.13M | 45.77M | 39.15M | 33.90M | 30.01M |
Reconciled depreciation | 5.78M | 5.12M | 3.94M | 3.84M | 3.09M |
Ebit | -8.10386M | -4.41856M | -3.11537M | -0.26471M | 1.22M |
Ebitda | -2.32861M | 0.70M | 0.82M | 3.57M | 4.31M |
Depreciation and amortization | 5.78M | 5.12M | 3.94M | 3.84M | 3.09M |
Non operating income net other | - | - | - | - | - |
Operating income | -8.32946M | -4.07263M | -4.13146M | -0.65138M | -0.94098M |
Other operating expenses | 95.49M | 87.69M | 76.71M | 63.36M | 58.24M |
Interest expense | 3.17M | 2.63M | 0.38M | 0.47M | 0.47M |
Tax provision | 0.97M | 0.82M | 0.93M | 0.35M | 1.19M |
Interest income | 0.03M | 0.00201M | 0.00043M | 0.00395M | 0.01M |
Net interest income | -3.13670M | -2.62469M | -0.37990M | -0.46523M | -0.30618M |
Extraordinary items | - | -0.13214M | -0.01066M | -0.10995M | -0.68023M |
Non recurring | - | - | - | - | - |
Other items | - | - | - | - | - |
Income tax expense | 0.97M | 0.82M | 0.93M | 0.35M | 1.19M |
Total revenue | 91.65M | 83.62M | 72.58M | 62.71M | 57.30M |
Total operating expenses | 63.46M | 49.84M | 43.28M | 34.56M | 30.96M |
Cost of revenue | 36.52M | 37.85M | 33.43M | 28.80M | 27.28M |
Total other income expense net | -2.94117M | -2.97263M | 0.64M | -0.08252M | -0.46240M |
Discontinued operations | - | -0.13214M | -0.01066M | -0.10995M | -0.68023M |
Net income from continuing ops | -12.24173M | -7.86690M | -4.42630M | -1.08306M | -0.43831M |
Net income applicable to common shares | - | -7.99904M | -4.43697M | -1.19301M | -1.11854M |
Preferred stock and other adjustments | - | - | - | - | - |
Breakdown | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 |
Total assets | 69.80M | 62.49M | 58.09M | 56.17M | 61.69M |
Intangible assets | - | 12.48M | 9.41M | 2.32M | 1.46M |
Earning assets | - | - | - | - | - |
Other current assets | 4.43M | 0.32M | 0.27M | 0.13M | 0.21M |
Total liab | 24.78M | 40.09M | 30.31M | 24.01M | 27.86M |
Total stockholder equity | 45.02M | 22.40M | 27.79M | 32.16M | 33.84M |
Deferred long term liab | - | 9.67M | 6.62M | 1.25M | 0.30M |
Other current liab | 4.05M | 3.20M | 11.18M | 5.86M | 10.50M |
Common stock | 110.23M | 74.27M | 74.27M | 74.26M | 73.94M |
Capital stock | - | 74.27M | 74.27M | 74.26M | 73.94M |
Retained earnings | -74.53666M | -62.29494M | -54.29589M | -49.85891M | -48.66591M |
Other liab | - | 0.79M | 1.18M | 0.86M | 0.83M |
Good will | 6.34M | 6.49M | 6.04M | 6.26M | 6.47M |
Other assets | - | 3.25M | 9.83M | 4.37M | 3.59M |
Cash | 16.18M | 11.96M | 15.64M | 21.11M | 30.17M |
Cash and equivalents | - | 11.96M | 15.64M | 21.11M | 30.17M |
Total current liabilities | 19.94M | 18.36M | 23.77M | 16.20M | 18.78M |
Current deferred revenue | 0.18M | 0.00153M | -6.65729M | -1.95602M | -7.57577M |
Net debt | -9.45907M | 11.55M | -3.63400M | -12.20223M | -14.64436M |
Short term debt | 2.60M | 2.57M | 6.66M | 1.96M | 7.28M |
Short long term debt | - | 0.31M | 4.88M | - | 4.95M |
Short long term debt total | 6.72M | 23.51M | 12.01M | 8.91M | 15.53M |
Other stockholder equity | 9.33M | -21.76422M | -29.76327M | -34.20024M | -35.39324M |
Property plant equipment | - | 12.73M | 9.12M | 10.34M | 10.24M |
Total current assets | 35.14M | 27.50M | 30.32M | 34.13M | 40.23M |
Long term investments | - | - | - | - | - |
Net tangible assets | - | 13.10M | 18.96M | 24.83M | 26.21M |
Short term investments | - | - | - | - | - |
Net receivables | 8.24M | 8.71M | 8.93M | 8.09M | 7.61M |
Long term debt | - | 16.36M | 2.01M | 2.35M | 2.51M |
Inventory | 6.29M | 4.10M | 3.09M | 2.33M | 2.24M |
Accounts payable | 13.11M | 12.59M | 12.59M | 10.33M | 8.57M |
Total permanent equity | - | - | - | - | - |
Noncontrolling interest in consolidated entity | - | - | - | - | - |
Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
Accumulated other comprehensive income | - | 10.43M | 7.81M | 7.76M | 8.56M |
Additional paid in capital | - | - | - | - | - |
Common stock total equity | - | - | - | - | 73.94M |
Preferred stock total equity | - | - | - | - | - |
Retained earnings total equity | - | - | - | - | - |
Treasury stock | - | - | - | - | - |
Accumulated amortization | - | - | - | - | - |
Non currrent assets other | 13.97M | -22.03566M | -17.94336M | -17.66934M | 0.12M |
Deferred long term asset charges | - | - | - | - | - |
Non current assets total | 34.67M | 35.00M | 27.78M | 22.04M | 21.46M |
Capital lease obligations | - | 6.84M | 5.12M | 6.56M | 8.07M |
Long term debt total | - | 20.94M | 5.35M | 6.95M | 8.25M |
Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
Investments | -6.41458M | 0.32M | -0.27147M | 0.31M | 0.31M |
Change to liabilities | -1.88181M | 2.34M | 1.99M | 0.68M | 0.32M |
Total cashflows from investing activities | -6.41458M | -8.47177M | -4.36857M | -1.82801M | -1.63447M |
Net borrowings | 6.61M | 2.09M | -7.20332M | 2.60M | 2.44M |
Total cash from financing activities | 6.61M | 2.09M | -6.80435M | 18.87M | 2.38M |
Change to operating activities | 0.03M | 0.70M | 1.06M | -0.34333M | 1.25M |
Net income | -7.99904M | -4.43697M | -1.19301M | -1.11854M | -0.03939M |
Change in cash | -3.68792M | -5.46551M | -9.06440M | 22.48M | -5.68633M |
Begin period cash flow | 15.64M | 21.11M | 30.17M | 7.70M | 13.38M |
End period cash flow | 11.96M | 15.64M | 21.11M | 30.17M | 7.70M |
Total cash from operating activities | -3.88020M | 1.86M | 2.71M | 5.19M | -6.54714M |
Issuance of capital stock | - | - | 0.40M | 16.88M | 0.01M |
Depreciation | 3.97M | 3.38M | 3.29M | 2.68M | 1.45M |
Other cashflows from investing activities | 0.00000M | 0.32M | -0.23647M | 0.36M | 0.03M |
Dividends paid | - | - | - | - | 4.96M |
Change to inventory | -1.01080M | -0.75944M | -0.08770M | -0.33884M | 0.25M |
Change to account receivables | 0.37M | -0.37342M | -2.86074M | 2.68M | 2.64M |
Sale purchase of stock | 0.00000M | 0.00000M | 0.40M | -0.61720M | -0.07350M |
Other cashflows from financing activities | 12.95M | 2.09M | -7.20332M | 2.60M | 9.40M |
Change to netincome | 1.68M | 0.46M | -0.03839M | 0.54M | 3.14M |
Capital expenditures | 6.41M | 8.79M | 4.13M | 2.19M | 1.66M |
Change receivables | - | - | - | - | - |
Cash flows other operating | - | - | - | - | - |
Exchange rate changes | - | - | - | - | - |
Cash and cash equivalents changes | - | - | - | - | - |
Change in working capital | -0.64406M | -1.13286M | -2.94844M | 2.34M | 0.04M |
Stock based compensation | 1.04M | 1.19M | 0.07M | 0.42M | - |
Other non cash items | 0.15M | 2.92M | 0.61M | 3.63M | 14.99M |
Free cash flow | -10.29479M | -6.93064M | -1.42633M | 3.00M | -8.20981M |
Sector: Healthcare Industry: Medical Devices
Company | Change (AUD) | Price (AUD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
---|---|---|---|---|---|---|---|---|
SOM SomnoMed Ltd |
0.01 1.61% | 0.63 | - | - | 1.34 | 2.89 | 1.24 | 40.34 |
COH Cochlear Ltd |
-2.78 1.02% | 268.49 | 48.10 | 38.76 | 7.68 | 9.45 | 7.58 | 29.32 |
PNV Polynovo Ltd |
-0.03 2.24% | 1.31 | 134.00 | 63.69 | 8.01 | 12.26 | 7.90 | 99.22 |
IMR Imricor Medical Systems Inc |
-0.04 2.35% | 1.66 | - | - | 552.77 | 3.97 | 372.97 | -2.6027 |
EBR Ebr Systems Inc CDR |
0.06 4.96% | 1.17 | - | - | - | 18.15 | -3.6785 |
SomnoMed Limited, together with its subsidiaries, produce and sells devices for the oral treatment of sleep related disorders in the Asia Pacific region, North America, and Europe. It provides SomnoDent Avant, as well as SomnoDent Classic, SomnoDent Flex, and SomnoDent Fusion are offered for the treatment of obstructive sleep apnea. The company also offers SomMorning Repositioner, a product designed to help return patient's mandible back to its pre-treatment centric position; SomnoBrux splint, a custom fit, acrylic splint for patient's upper teeth designed to protect teeth from grinding and scraping during Bruxism; and SomTabs, which are cleaning tablets to clean oral appliances. In addition, it provides Sunrise, a bio-signal to diagnose sleep apnea. The company was incorporated in 1987 and is headquartered in Crows Nest, Australia.
20 Clarke Street, Crows Nest, NSW, Australia, 2065
Name | Title | Year Born |
---|---|---|
Mr. Neil Verdal-Austin B.Com., C.A. | Global CEO, MD & Director | NA |
Mr. Hervé Fiévet | Global Chief Financial Officer | NA |
Mr. Mark Harding | VP of Global Marketing | NA |
Mr. Matthew Conlon | Exec. VP Sales & Marketing - North America | NA |
Mr. Marco Van Kleef | VP of Marketing & Sales - Europe | NA |
Dr. Jagdeep Bijwadia | Chief Medical Officer | NA |
Mr. Terence A. Flitcroft B.Com., B.Comm., C.A., CA, SF FIN | Company Sec. | 1959 |
Dr. Peter Spencer MBA Ph.D., MAICD | Gen. Mang. of Operations | 1956 |
Mr. Christopher Bedford | VP of Global Production and Product Devel. | NA |
Mr. Mark Harding | Vice President of Global Marketing | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes. This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API. Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.